Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats
Open accessThe DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Synaptic dysfunction is hypothesised to play a key role in schizophrenia pathogenesis, but this has not been tested directly in vivo. Here, we investigated synaptic vesicle glycoprotein 2A (SV2A) levels and their relationship to symptoms and structural brain measures using [ 11 C]UCB-J positron emission tomography in 18 patients with schizophrenia and 18 controls. We found significant group and group-by-region interaction effects on volume of distribution ( V T ). [ 11 C]UCB-J V T was significantly lower in the frontal and anterior cingulate cortices in schizophrenia with large effect sizes (Cohen’s d = 0.8-0.9), but there was no significant difference in the hippocampus. We also investigated the effects of antipsychotic drug administration on SV2A levels in Sprague-Dawley rats using western blotting, [ 3 H]UCB-J autoradiography and immunostaining with confocal microscopy, finding no significant effects on any measure. These findings indicate that there are lower synaptic terminal protein levels in schizophrenia in vivo and that antipsychotic drug exposure is unlikely to account for them.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Regional mean [11C]UCB-J distribution volume (VT) by group. Grey bars depict regional mean VT in the healthy volunteer (HV) group, and triangles represent individual HV VT (n = 18). Hollow bars depict mean VT in the schizophrenia (SCZ) group, and circles indicate individual SCZ patient VT (n = 18). p Values reported here are FDR-adjusted p values. [11C]UCB-J VT was significantly reduced with large effect sizes (Cohen’s d > 0.8) in the SCZ compared to the HV group in the frontal cortex and anterior cingulate cortex (ACC). [11C]UCB-J VT was not significantly altered in the hippocampus. Error bars indicate standard error of the mean.](https://figures.cochat.ai/paper-figures/5b96f86cce9c4f2590ae5ddc78485e55/synaptic-density-marker-sv2a-is-reduced-in-schizophrenia-patients-and-unaffected-figure-1.jpg)
![Fig. 2 Mean parametric [11C]UCB-J VT images from healthy volunteer (HV) and schizophrenia (SCZ) groups. Colour bar indicates [11C]UCB-J VT.](https://figures.cochat.ai/paper-figures/0715a47ea70f4f4dab930d21ac8a32a9/synaptic-density-marker-sv2a-is-reduced-in-schizophrenia-patients-and-unaffected-figure-2.jpg)
![Fig. 3 Regional mean [11C]UCB-J distribution volume ratio (DVR) group. Grey bars depict regional mean DVR in the healthy volunteer (HV) group, and triangles represent individual HV DVR (n = 18). Hollow bars depict mean DVR in the schizophrenia (SCZ) group, and circles indicate individual SCZ patient DVR (n = 18). FDR-adjusted p values from post-hoc t-tests are reported here. [11C]UCB-J DVR was significantly reduced with large effect sizes (Cohen’s d > 0.8) in the SCZ compared to the HV group in the frontal cortex, anterior cingulate cortex (ACC) and the hippocampus. Error bars indicate standard error of the mean.](https://figures.cochat.ai/paper-figures/e0c5c627df9046fc9ce9c1007b6b7c7b/synaptic-density-marker-sv2a-is-reduced-in-schizophrenia-patients-and-unaffected-figure-3.jpg)
![Fig. 4 Chronic haloperidol administration does not affect SV2A levels in the rat frontal cortex (FC). a Example of western blots showing total SV2A levels in synaptosomes isolated from the FC. b Quantification of total SV2A levels on western blot, normalised to GAPDH, showed no significant changes upon chronic haloperidol treatment (Kruskal–Wallis test, p = 0.71). c Autoradiography images of brain sections incubated with 12.5 nM [3H]UCB-J in absence (left) or presence (right) of levetiracetam (a drug that binds to SV2A). Black boxes indicate which ROI was selected to measure tracer binding in the prefrontal cortex, PFC (top), or anterior cingulate cortex, ACC (bottom). WM, white matter. Colour bar indicates [3H]UCB-J binding levels. Scale bar, 1 mm d Quantification of [3H]UCB-J binding in PFC (top) and ACC (bottom), indicating no significant changes upon chronic haloperidol treatment (two-way ANOVA, F2,12 = 1.451, p = 0.27). e Top: schematic of brain section at Bregma 1.1 mm. Bottom: low magnification fluorescent image of a rat brain section immunostained for SV2A (red) and DAPI (blue). Scale bar, 250 µm. ACC, anterior cingulate cortex; WM, white matter; STR, striatum. f High-magnification confocal images of brain sections from vehicle- (top) or haloperidol- (bottom) treated animals, showing punctate immunostaining for SV2A. Both raw images (left hand side) as well as background corrected images (right hand side) are shown. White arrows indicate a lack of SV2A punctae in the cell body; yellow arrows indicate examples of presynaptic terminals at perisomatic synapses and proximal dendrites. Scale bar, 10 µm (large field of view) or 4 µm (zoomed insets). g Quantification of background corrected SV2A intensity values. There were no significant differences in SV2A immunostaining intensity between vehicle- and haloperidol-treated groups (two-way ANOVA with Bonferroni’s multiple comparison correction, F1,20 = 0.1412, p = 0.71). Error bars indicate standard error of the mean.](https://figures.cochat.ai/paper-figures/9ed83cfdc33141eabda7f625abed0f1b/synaptic-density-marker-sv2a-is-reduced-in-schizophrenia-patients-and-unaffected-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PET studies on several neuropsychiatric disorders linked to synaptic dysfunction, including depression, have found lower cerebral SV2A density in patients compared to healthy individuals [17–22].”
From Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial (2023) · cites this paper as [21]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The use of VTs also make our results more easily comparable to other [11C]UCB-J PET studies on related topics [20–23, 53, 57, 58].”
From Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial (2023) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“Similar results were observed in patients with schizophrenia (107).”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [107]
In the citing paper
“positron emission tomography studies have shown increased synaptic density in sensory cortices and decreased synaptic density in superior frontal areas in people at risk for psychotic symptoms.”
From Towards an Integrative Account of Potential Mechanisms Mediating the Path From Sleep Dysfunction to Hallucinations (2025) · cites this paper as [95]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319
Implications of Normal Brain Development for the Pathogenesis of Schizophrenia
Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724
Schizophrenia risk from complex variation of complement component 4
Sekar, A., Bialas, A. R., de Rivera, H., Davis, A., Hammond, T. R., Kamitaki, N., Tooley, K., Presumey, J., Baum, M., Van Doren, V., et al. (2016) · Nature · doi:10.1038/nature16549 · Cited by 2,394
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Self-citationDecreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia
Glantz, L. A., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.65 · Cited by 1,636
De novo mutations in schizophrenia implicate synaptic networks
Fromer, M., Pocklington, A. J., Kavanagh, D. H., Williams, H. J., Dwyer, S., Gormley, P., Georgieva, L., Rees, E., Palta, P., Ruderfer, D. M., et al. (2014) · Nature · doi:10.1038/nature12929 · Cited by 1,617
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
Cited by
Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
McCutcheon, R. A., Keefe, R. S. E., & McGuire, P. K. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01949-9 · Cited by 741
Mechanisms governing activity-dependent synaptic pruning in the developing mammalian CNS
Faust, T. E., Gunner, G., & Schafer, D. P. (2021) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00507-y · Cited by 437
Radiopharmaceuticals and their applications in medicine
Zhang, S., Wang, X., Gao, X., Chen, X., Li, L., Li, G., Liu, C., Miao, Y., Wang, R., & Hu, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02041-6 · Cited by 284
Howes, O. D., & Shatalina, E. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.06.017 · Cited by 256
“Both showed significantly lower SV2A density in the patient groups in the frontal and anterior cingulate cortices (46, 47).”
Self-citationHowes, O. D., Whitehurst, T., Shatalina, E., Townsend, L., Onwordi, E. C., Mak, T. L. A., Arumuham, A., O’Brien, O., Lobo, M., Vano, L., et al. (2021) · World Psychiatry · doi:10.1002/wps.20822 · Cited by 243
Self-citation
Metadata
- Authors
- Onwordi, E. C., Halff, E. F., Whitehurst, T., Mansur, A., Cotel, M.-C., Wells, L., Creeney, H., Bonsall, D., Rogdaki, M., Shatalina, E., Reis Marques, T., Rabiner, E. A., Gunn, R. N., Natesan, S., Vernon, A. C., & Howes, O. D.
- Affiliations
- King's College London (GB)
- Hammersmith Hospital (GB)
- Invicro (United Kingdom) (GB)
- Corresponding author
- Howes, Oliver D.
- ORCID
- Venue
- Nature Communications
- Published
- 2020-01-14
- Volume
- 11
- Issue
- 1
- Pages
- 246-246
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC6959348
- OpenAlex
- W2997938254
- Cited by
- 243
- References
- 88
- Citations by year
- 2026: 21 · 2025: 32 · 2024: 44 · 2023: 33 · 2022: 45 · 2021: 41 · 2020: 26
- FWCI
- 26.29
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Research Portal (King's College London) (submittedVersion, cc-by)
- Spiral (Imperial College London) (submittedVersion, other-oa)
- Funders
- RCUK | Medical Research Council
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- schizophrenia, synaptic density, SV2A, antipsychotic drugs, synaptic dysfunction, volume of distribution, frontal cortex, anterior cingulate cortex, hippocampus
- MeSH terms
- Animals, Brain, Female, Frontal Lobe, Gyrus Cinguli, Humans, Male, Membrane Glycoproteins, Nerve Tissue Proteins, Organ Specificity, Pyridines, Pyrrolidinones, Schizophrenia, Antipsychotic Agents, Rats, Sprague-Dawley, Positron-Emission Tomography, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. https://app.cochat.ai/papers/10.1038/s41467-019-14122-0
- The paper
- Onwordi, E. C., Halff, E. F., Whitehurst, T., Mansur, A., Cotel, M.-C., Wells, L., Creeney, H., Bonsall, D., Rogdaki, M., Shatalina, E., Reis Marques, T., Rabiner, E. A., Gunn, R. N., Natesan, S., Vernon, A. C., & Howes, O. D. (2020). Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nature Communications. https://doi.org/10.1038/s41467-019-14122-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.